Publication | Closed Access

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

OncologyMedicinePharmacotherapyAnti-cancer AgentAdvanced MalignanciesCancer TreatmentPharmacologyCancer ResearchDrug Discovery